DOP2012000105A - Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes - Google Patents
Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetesInfo
- Publication number
- DOP2012000105A DOP2012000105A DO2012000105A DO2012000105A DOP2012000105A DO P2012000105 A DOP2012000105 A DO P2012000105A DO 2012000105 A DO2012000105 A DO 2012000105A DO 2012000105 A DO2012000105 A DO 2012000105A DO P2012000105 A DOP2012000105 A DO P2012000105A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- same
- pharmaceutical use
- treat diabetes
- spiropiperidine compounds
- spiropiperidine
- Prior art date
Links
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25183909P | 2009-10-15 | 2009-10-15 | |
| US30333410P | 2010-02-11 | 2010-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2012000105A true DOP2012000105A (es) | 2013-01-31 |
Family
ID=43719548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2012000105A DOP2012000105A (es) | 2009-10-15 | 2012-04-13 | Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8383642B2 (https=) |
| EP (1) | EP2488500A1 (https=) |
| JP (1) | JP2013508279A (https=) |
| KR (1) | KR20120051777A (https=) |
| CN (1) | CN102574807A (https=) |
| AR (1) | AR078522A1 (https=) |
| AU (1) | AU2010307094A1 (https=) |
| BR (1) | BR112012008889A2 (https=) |
| CA (1) | CA2777775A1 (https=) |
| CL (1) | CL2012000921A1 (https=) |
| CO (1) | CO6531458A2 (https=) |
| CR (1) | CR20120177A (https=) |
| DO (1) | DOP2012000105A (https=) |
| EA (1) | EA201270560A1 (https=) |
| EC (1) | ECSP12011799A (https=) |
| IL (1) | IL218344A0 (https=) |
| MA (1) | MA33662B1 (https=) |
| MX (1) | MX2012004420A (https=) |
| NZ (1) | NZ598972A (https=) |
| PE (1) | PE20121437A1 (https=) |
| PH (1) | PH12012500705A1 (https=) |
| TN (1) | TN2012000152A1 (https=) |
| TW (1) | TW201124415A (https=) |
| WO (1) | WO2011046851A1 (https=) |
| ZA (1) | ZA201202560B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2411393T1 (sl) | 2009-03-23 | 2014-03-31 | Glenmark Pharmaceuticals S.A. | Kondenzirani pirimidin-dionski derivati kot TRPA 1 modulatorji |
| EP2411395B1 (en) | 2009-03-23 | 2013-05-29 | Glenmark Pharmaceuticals S.A. | Furopyrimidinedione derivatives as trpa1 modulators |
| AR078948A1 (es) * | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
| CN104710381A (zh) | 2009-12-25 | 2015-06-17 | 持田制药株式会社 | 新的3-羟基-5-芳基异噻唑衍生物 |
| JP5809157B2 (ja) | 2010-10-08 | 2015-11-10 | 持田製薬株式会社 | 環状アミド誘導体 |
| CN103517637B (zh) | 2011-03-11 | 2015-12-02 | 洲际大品牌有限责任公司 | 形成多层糖食的系统和方法 |
| RU2013152631A (ru) | 2011-04-27 | 2015-06-10 | Мотида Фармасьютикал Ко., Лтд. | Новое 3-гидроксиизотиазол-1-окидное производное |
| JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
| TWI537262B (zh) * | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物 |
| WO2013139341A1 (en) * | 2012-03-20 | 2013-09-26 | Syddansk Universitet | Gpr120 receptor modulators |
| WO2013185766A1 (en) * | 2012-06-15 | 2013-12-19 | Syddansk Universitet | Gpr120 receptor modulators |
| RS55363B1 (sr) | 2012-11-16 | 2017-03-31 | Bristol Myers Squibb Co | Dihidropirazolni gpr40 modulatori |
| KR101569522B1 (ko) * | 2013-04-18 | 2015-11-17 | 현대약품 주식회사 | 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| EP3068788A1 (en) * | 2013-11-14 | 2016-09-21 | Cadila Healthcare Limited | Novel heterocyclic compounds |
| US20150351889A1 (en) | 2014-06-05 | 2015-12-10 | Vivex Biomedical Inc. | Dynamic Biometric Mesh |
| MX387086B (es) | 2014-10-17 | 2025-03-19 | Hyundai Pharm Co Ltd | Preparacion compuesta, que contiene derivado novedoso de acido 3-(4-(benciloxi)fenil)hex-4-inoico y otro ingrediente activo, para prevenir o tratar enfermedades metabolicas |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| CN109666027A (zh) * | 2017-10-17 | 2019-04-23 | 中国科学院上海药物研究所 | 一类酰胺结构的gpr40激动剂化合物及其用途 |
| US11964938B2 (en) | 2018-01-08 | 2024-04-23 | Celon Pharma S.A. | 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| SG11202012425QA (en) | 2018-07-13 | 2021-01-28 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR20220150270A (ko) | 2019-10-07 | 2022-11-10 | 칼리오페, 인크. | Gpr119 효능제 |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4489354B2 (ja) | 2001-04-18 | 2010-06-23 | ユーロ−セルティーク エス．エイ． | スピロインデンおよびスピロインダン化合物類 |
| CN1768041A (zh) | 2003-04-04 | 2006-05-03 | 麦克公司 | 作为黑皮质素－4受体激动剂的酰化螺哌啶衍生物 |
| US7504506B2 (en) | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US7834013B2 (en) | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
| CA2558585C (en) | 2004-02-27 | 2010-10-12 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders |
| US7517910B2 (en) | 2004-03-30 | 2009-04-14 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| CA2662242C (en) | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| BRPI0818687A2 (pt) | 2007-10-26 | 2017-05-02 | Japan Tobacco Inc | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. |
| JP2011504499A (ja) | 2007-11-21 | 2011-02-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トリプターゼ阻害剤として使用するためのスピロピペリジン |
| AR078948A1 (es) | 2009-11-30 | 2011-12-14 | Lilly Co Eli | Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes |
-
2010
- 2010-10-04 AR ARP100103604A patent/AR078522A1/es not_active Application Discontinuation
- 2010-10-06 TW TW099134098A patent/TW201124415A/zh unknown
- 2010-10-11 CN CN2010800462763A patent/CN102574807A/zh active Pending
- 2010-10-11 KR KR1020127009501A patent/KR20120051777A/ko not_active Ceased
- 2010-10-11 EP EP10793349A patent/EP2488500A1/en not_active Withdrawn
- 2010-10-11 EA EA201270560A patent/EA201270560A1/ru unknown
- 2010-10-11 NZ NZ598972A patent/NZ598972A/xx not_active IP Right Cessation
- 2010-10-11 JP JP2012534259A patent/JP2013508279A/ja not_active Withdrawn
- 2010-10-11 PH PH1/2012/500705A patent/PH12012500705A1/en unknown
- 2010-10-11 US US12/901,597 patent/US8383642B2/en not_active Expired - Fee Related
- 2010-10-11 WO PCT/US2010/052126 patent/WO2011046851A1/en not_active Ceased
- 2010-10-11 BR BR112012008889A patent/BR112012008889A2/pt not_active IP Right Cessation
- 2010-10-11 MX MX2012004420A patent/MX2012004420A/es not_active Application Discontinuation
- 2010-10-11 AU AU2010307094A patent/AU2010307094A1/en not_active Abandoned
- 2010-10-11 PE PE2012000492A patent/PE20121437A1/es not_active Application Discontinuation
- 2010-10-11 CA CA2777775A patent/CA2777775A1/en not_active Abandoned
-
2012
- 2012-02-27 IL IL218344A patent/IL218344A0/en unknown
- 2012-04-02 TN TNP2012000152A patent/TN2012000152A1/en unknown
- 2012-04-09 MA MA34760A patent/MA33662B1/fr unknown
- 2012-04-10 ZA ZA2012/02560A patent/ZA201202560B/en unknown
- 2012-04-12 CL CL2012000921A patent/CL2012000921A1/es unknown
- 2012-04-12 CR CR20120177A patent/CR20120177A/es not_active Application Discontinuation
- 2012-04-13 EC ECSP12011799 patent/ECSP12011799A/es unknown
- 2012-04-13 DO DO2012000105A patent/DOP2012000105A/es unknown
- 2012-04-20 CO CO12065315A patent/CO6531458A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA33662B1 (fr) | 2012-10-01 |
| CA2777775A1 (en) | 2011-04-21 |
| CL2012000921A1 (es) | 2012-09-14 |
| WO2011046851A1 (en) | 2011-04-21 |
| KR20120051777A (ko) | 2012-05-22 |
| EP2488500A1 (en) | 2012-08-22 |
| IL218344A0 (en) | 2012-04-30 |
| US8383642B2 (en) | 2013-02-26 |
| AU2010307094A1 (en) | 2012-04-19 |
| NZ598972A (en) | 2013-06-28 |
| MX2012004420A (es) | 2012-05-08 |
| PH12012500705A1 (en) | 2012-10-29 |
| ZA201202560B (en) | 2013-09-25 |
| PE20121437A1 (es) | 2012-10-26 |
| BR112012008889A2 (pt) | 2019-09-24 |
| EA201270560A1 (ru) | 2012-09-28 |
| TW201124415A (en) | 2011-07-16 |
| CR20120177A (es) | 2012-06-06 |
| ECSP12011799A (es) | 2012-07-31 |
| US20110092531A1 (en) | 2011-04-21 |
| CN102574807A (zh) | 2012-07-11 |
| JP2013508279A (ja) | 2013-03-07 |
| AR078522A1 (es) | 2011-11-16 |
| TN2012000152A1 (en) | 2013-12-12 |
| CO6531458A2 (es) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2012000105A (es) | Compuestos de espiropiperidina y uso farmaceutico del mismo para tratar la diabetes | |
| CR20140161A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| DOP2011000260A (es) | Pirimidinas fusionadas | |
| CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
| MX354021B (es) | Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona. | |
| UY34750A (es) | ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?. | |
| UY33503A (es) | Imidazo [1,2-a]pirimidinas y piridinas sustituidas | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| CL2016001737A1 (es) | Derivados heterocíclicos bicíclicos como inhibidores de bromodominio | |
| UA107951C2 (xx) | Похідні імідазопіридину як інгібітори jak | |
| PE20141406A1 (es) | 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio | |
| CU20090148A7 (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y su uso | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| GT201400111A (es) | Triazolopiridinas sustituidas | |
| CR20120296A (es) | Nuevos compuestos de espiropiperidina | |
| ECSP13012520A (es) | Proceso para la preparación de inhibidores de pan-cdk de la fórmula (i), e intermediarios de la preparación | |
| UY32153A (es) | Inhibidores de piridomidinona de pi13ka(alfa) y mtor | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| EA201390799A1 (ru) | Триазолопиридины | |
| EA201490599A1 (ru) | Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a | |
| AR085616A1 (es) | Composicion farmaceutica inhalable que comprende glicopirrolato, uso | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| CR20140257A (es) | Nuevos 2h-indazoles como antagonistas del receptor ep2 | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| EA201491227A1 (ru) | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 |